Strategic partnerships Isogenica has established and expanding collaborations with major players (Charles River Laboratories, Cube Biotech) and ongoing visibility through industry events, signaling a strong appetite for co-development and platform integration opportunities with CROs, biotech developers, and academic partners.

Platform leverage With CIS Display and large synthetic VHH libraries enabling 100–1000x higher screening throughput, target customers seeking faster discovery timelines and higher developability screening can be positioned to adopt Isogenica as a core acceleration partner.

Clinical momentum Multiple clinical-stage programmes and a track record of converting discovery into clinically progressing assets provide a credibility anchor for identifying biotech and pharma teams looking to de-risk early R&D and shorten time to clinic.

Global exposure Active participation in Europe and the UK biotech ecosystem through events such as PEGS Europe and UK Biotech Day, along with a Cambridge UK hub narrative, creates touchpoints for international biotech and investors seeking collaborative discovery partners.

Growth-ready fit Revenue and funding levels suggest Isogenica is at a growth stage with scalable discovery capabilities; target sales can focus on expanding library access, automated humanization pipelines, and integration with partner workflows to broaden adoption across biotech SMEs and early-stage pharma.